SLFN11 and breast carcinoma: For breast cancer patients with low SLFN11 expression, preclinical evidence (56) suggests that the combination of DDA (such as gemcitabine) and ATR/WEE1/CHK1 inhibitors (such as AZD6738) may be an effective treatment strategy to overcome their potential drug resistance.